Ondansetron Augmentation in Treatment-resistant OCD | NCT01303536 | Trialant

Ondansetron Augmentation in Treatment-resistant OCD | NCT01303536 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
obsessive compulsive disorder	Experimental	obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly	Drug: Ondansetron

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Ondansetron	Drug	obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Yale Brown Obsessive Compulsive Scale		baseline
Yale Brown Obsessive Compulsive Scale		week 2
Yale Brown Obsessive Compulsive Scale		week 4
Yale Brown Obsessive Compulsive Scale		week 6
Yale Brown Obsessive Compulsive Scale		week 8
Yale Brown Obsessive Compulsive Scale		week 10
Yale Brown Obsessive Compulsive Scale		week 12
Yale Brown Obsessive Compulsive Scale		week 14
Yale Brown Obsessive Compulsive Scale		week 16

Contacts/Locations Module

Intervention Browse Module